Disease overview

Alterations

110

Molecular (A)

100

Clinical (B–E)

Direct drugs

358

Via biomarker

453

Natural agents

Natural products

Merged ranked

807

With trial/literature evidence

Sources: Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, PubMed Literature, GreenMedInfo, Examine.com · Pipeline phase 7 · Updated 2026-07-06

Remission & chronicity

Spontaneous remission

Early-stage (Rai 0-I): watch-and-wait appropriate in 50-70%; spontaneous remission extremely rare; median time to treatment in Rai Stage 0: 10+ years; Richter's transformation (5-10%) extremely poor prognosis

Best-intervention remission

Venetoclax + obinutuzumab (CLL14): 2-year fixed duration, MRD-undetectable remission in 36%, PFS benefit sustained at 5 years vs chlorambucil; ibrutinib continuous: PFS benefit but not curative; BRUIN CLL trial (pirtobrutinib): 73% ORR in ibrutinib-resistant CLL

Drug-free remission

—

Relapse after remission

—

Chronicity

—

Gap size

Large — chlorambucil still used in some elderly patients; BTK inhibitor choice and venetoclax combination timing are practice-variable

Primary barrier

practice/access

Barrier detail: Chemoimmunotherapy (FCR, BR) largely replaced by BTK inhibitors and venetoclax but chlorambucil still used where cost is a barrier; the 'best drug at first relapse' question is evolving rapidly; CAR-T not yet standard for CLL

Last SoC change: 2023 — pirtobrutinib (non-covalent BTKi) for ibrutinib-resistant CLL; 2020 venetoclax + obinutuzumab fixed-duration; 2019 ibrutinib first-line approved; fludarabine + cyclophosphamide + rituximab (FCR) as standard 2006-2019; chlorambucil since 1950s

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0004948

Alterations

Showing 80 of 110 · Types A (molecular) through E (functional)

Name	Type	Subtype	Direction	Frequency	Evidence	Sources	Links
Cellular immunodeficiency	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
Chronic lymphatic leukemia	Pathology	Pathological finding	—	—	Moderate	HPO, Monarch	HPO
ABL1 ABL proto-oncogene 1, non-receptor tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ACOXL acyl-CoA oxidase like	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ACTA2 actin alpha 2, smooth muscle	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ADA adenosine deaminase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
AR androgen receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ARID1A AT-rich interaction domain 1A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ARL11 ARF like GTPase 11	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ASXL1 ASXL transcriptional regulator 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ATM ATM serine/threonine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
ATR ATR checkpoint kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Assess the exploratory efficacy of the combination ABT-199 and rituximab	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
BAK1 BCL2 antagonist/killer 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BANK1 B cell scaffold protein with ankyrin repeats 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BCL2 BCL2 apoptosis regulator	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BCL2L11 BCL2 like 11	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BCOR BCL6 corepressor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BCR BCR activator of RhoGEF and GTPase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BIRC3 baculoviral IAP repeat containing 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BMF Bcl2 modifying factor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BRAF B-Raf proto-oncogene, serine/threonine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
BTK Bruton tyrosine kinase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
C11orf21 chromosome 11 open reading frame 21	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CAMK2D calcium/calmodulin dependent protein kinase II delta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CCND2 cyclin D2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CD19 CD19 molecule	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CD22 CD22 molecule	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CD52 CD52 molecule	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDK6 cyclin dependent kinase 6	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CDKN1B cyclin dependent kinase inhibitor 1B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CHD2 chromodomain helicase DNA binding protein 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CHEK2 checkpoint kinase 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CRBN cereblon	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CREBBP CREB binding lysine acetyltransferase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CSF3R colony stimulating factor 3 receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
CUL4A cullin 4A	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Change in cognitive and mental health	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Complete Response Rate	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
DDB1 damage specific DNA binding protein 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DDX3X DEAD-box helicase 3 X-linked	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
DNMT3A DNA methyltransferase 3 alpha	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Duration of Response (DOR)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
EBF1 EBF transcription factor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
EEF2 eukaryotic translation elongation factor 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
EOMES eomesodermin	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
EP300 EP300 lysine acetyltransferase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
EZH2 enhancer of zeste 2 polycomb repressive complex 2 subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FAS Fas cell surface death receptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FAT4 FAT atypical cadherin 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FBXW7 F-box and WD repeat domain containing 7	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
FUBP1 far upstream element binding protein 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
GRAMD1B GRAM domain containing 1B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IFNAR1 interferon alpha and beta receptor subunit 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IFNAR2 interferon alpha and beta receptor subunit 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IGLL5 immunoglobulin lambda like polypeptide 5	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IKZF3 IKAROS family zinc finger 3	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IRF4 interferon regulatory factor 4	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
IRF8 interferon regulatory factor 8	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KMT2D lysine methyltransferase 2D	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
KRAS KRas proto-oncogene, GTPase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
LEF1 lymphoid enhancer binding factor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
LRP1B LDL receptor related protein 1B	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MAP2K1 mitogen-activated protein kinase kinase 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MED12 mediator complex subunit 12	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MGA MAX dimerization protein MGA	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MS4A1 membrane spanning 4-domains A1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
MYD88 MYD88 innate immune signal transduction adaptor	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NFKBIE NFKB inhibitor epsilon	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NOTCH1 notch receptor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NOTCH2 notch receptor 2	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NRAS NRAS proto-oncogene, GTPase	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
NXF1 nuclear RNA export factor 1	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
Overall Response Rate (ORR)	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
Overall Survival	Lab / Clinical	Lab value	—	—	Emerging	ClinicalTrials.gov	—
PIK3CD phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
PIK3CG phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLA1 DNA polymerase alpha 1, catalytic subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLA2 DNA polymerase alpha 2, accessory subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets
POLD1 DNA polymerase delta 1, catalytic subunit	Molecular	Gene	—	—	Emerging	Open Targets	UniProt Ensembl Open Targets

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, merged ranking, and clinical trial / literature evidence (top agents)

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
SIROLIMUS	Small molecule	Approved	Strong	105	8 trials View evidence Registry trials NCT00671112 — Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma (TERMINATED) PHASE1 NCT01244906 — Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant (COMPLETED) PHASE2 NCT00589563 — Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer (COMPLETED) PHASE2 NCT00105001 — Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer (COMPLETED) PHASE2 NCT00918333 — Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma (COMPLETED) PHASE1, PHASE2 NCT00544115 — Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders (ACTIVE_NOT_RECRUITING) PHASE2 NCT02226861 — Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation (COMPLETED) PHASE1 NCT01231412 — Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant (COMPLETED) PHASE3 CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
CIPROFLOXACIN	Small molecule	Approved	Strong	100	3 trials View evidence Registry trials NCT01279252 — CLL Empirical Antibiotic Regimen (COMPLETED) PHASE2 NCT00062231 — Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer (TERMINATED) NA NCT00445497 — Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia (UNKNOWN) PHASE3 CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
EPIRUBICIN	Small molecule	Approved	Strong	100	1 trials View evidence Registry trials NCT00062296 — Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
TACROLIMUS ANHYDROUS	Small molecule	Approved	Strong	100	8 trials View evidence Registry trials NCT00057954 — Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma (TERMINATED) PHASE2 NCT00143845 — Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant (COMPLETED) PHASE2 NCT00818961 — Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer (TERMINATED) PHASE2 NCT00423826 — Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease (NO_LONGER_AVAILABLE) NCT00004145 — Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer (COMPLETED) PHASE2 NCT00281879 — Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer (TERMINATED) PHASE2 NCT00448201 — Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease (COMPLETED) PHASE2 NCT00589563 — Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	Open Targets, ChEMBL	ChEMBL Open Targets
3,3',4',5-TETRACHLOROSALICYLANILIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
4-PHENYLBUTYRIC ACID Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ABIRATERONE ACETATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ACETAZOLAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ACETOPHENAZINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ACYCLOVIR Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ADENOSINE TRIPHOSPHATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ALCLOFENAC Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ALCLOMETASONE DIPROPIONATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMCINONIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMDINOCILLIN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMIODARONE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMITRIPTYLINE HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMLEXANOX Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AMLODIPINE BESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMPHETAMINE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ANHYDROUS TACROLIMUS Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
APALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
APOMORPHINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ASCIMINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ASCIMINIB HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ASTEMIZOLE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATALUREN Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATEZOLIZUMAB Repurposing	Small molecule	Approved	Strong	95	5 trials View evidence Registry trials NCT02594384 — A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma (COMPLETED) PHASE1 NCT06043674 — Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation (RECRUITING) PHASE2 NCT02500407 — A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (COMPLETED) PHASE1, PHASE2 NCT02733042 — A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (COMPLETED) PHASE1, PHASE2 NCT02846623 — Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome (ACTIVE_NOT_RECRUITING) PHASE2 CT.gov search · Cochrane · PubMed	DGIdb	—
ATRACURIUM BESYLATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
ATROPINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AVELUMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AXITINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AZACITIDINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
AZARIBINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BECLOMETHASONE DIPROPIONATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BENAZEPRIL HYDROCHLORIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BENDAMUSTINE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BENORILATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BETAMETHASONE DIPROPIONATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE SODIUM PHOSPHATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE VALERATE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BICALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
BIFONAZOLE Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BINIMETINIB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BISACODYL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BITHIONOL Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—
BITHIONOLATE SODIUM Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BLINATUMOMAB Repurposing	Small molecule	Approved	Strong	95	—	DGIdb	—

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
ALVOCIDIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
APG-2575	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ARSENIC TRIOXIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
BENDAMUSTINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CLADRIBINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
CYCLOPHOSPHAMIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DARBEPOETIN ALFA	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DINACICLIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
DOXORUBICIN HYDROCHLORIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EPOETIN ALFA	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
EPOETIN BETA	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ERGOCALCIFEROL	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FILGRASTIM	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
FLUDARABINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
IRON SUCROSE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LENALIDOMIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
LISOCABTAGENE MARALEUCEL	Gene therapy	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
METHYLPREDNISOLONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
MITOXANTRONE HYDROCHLORIDE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NEMTABRUTINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
NX-5948	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
OBLIMERSEN SODIUM	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ORELABRUTINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PENTOSTATIN	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PIRTOBRUTINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
PREDNISONE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
ROCBRUTINIB	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SIROLIMUS	Small molecule	Phase III	Moderate	80	8 trials View evidence Registry trials NCT00671112 — Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma (TERMINATED) PHASE1 NCT01244906 — Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant (COMPLETED) PHASE2 NCT00589563 — Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer (COMPLETED) PHASE2 NCT00105001 — Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer (COMPLETED) PHASE2 NCT00918333 — Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma (COMPLETED) PHASE1, PHASE2 NCT00544115 — Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders (ACTIVE_NOT_RECRUITING) PHASE2 NCT02226861 — Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation (COMPLETED) PHASE1 NCT01231412 — Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant (COMPLETED) PHASE3 CT.gov search · Cochrane · PubMed	Open Targets	ChEMBL Open Targets
SONROTOCLAX	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
SUROVATAMIG	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TACROLIMUS	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TISAGENLECLEUCEL	Cell therapy	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
TISLELIZUMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
UBLITUXIMAB	Biologic	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
UMBRALISIB TOSYLATE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
VINCRISTINE	Small molecule	Phase III	Moderate	80	—	Open Targets	ChEMBL Open Targets
AFURESERTIB	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
ALDESLEUKIN	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AMINOLEVULINIC ACID HYDROCHLORIDE	Small molecule	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets
AMINOPHYLLINE	Biologic	Phase II	Emerging	60	—	Open Targets	ChEMBL Open Targets

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
3,3',4',5-TETRACHLOROSALICYLANILIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
4-PHENYLBUTYRIC ACID Repurposing via BCL2	Small molecule	Approved	Strong	95	—	DGIdb	—
ABIRATERONE ACETATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ACETAZOLAMIDE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ACETOPHENAZINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ACYCLOVIR Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
ADENOSINE TRIPHOSPHATE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
ALCLOFENAC Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ALCLOMETASONE DIPROPIONATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMCINONIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
AMDINOCILLIN Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
AMIODARONE HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMITRIPTYLINE HYDROCHLORIDE Repurposing via ADA	Small molecule	Approved	Strong	95	—	DGIdb	—
AMLEXANOX Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
AMLODIPINE BESYLATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
AMPHETAMINE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets
ANHYDROUS TACROLIMUS Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
APALUTAMIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
APOMORPHINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ASCIMINIB Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
ASCIMINIB HYDROCHLORIDE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
ASTEMIZOLE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ATALUREN Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ATEZOLIZUMAB Repurposing via ARID1A	Small molecule	Approved	Strong	95	5 trials View evidence Registry trials NCT02594384 — A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma (COMPLETED) PHASE1 NCT06043674 — Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation (RECRUITING) PHASE2 NCT02500407 — A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (COMPLETED) PHASE1, PHASE2 NCT02733042 — A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (COMPLETED) PHASE1, PHASE2 NCT02846623 — Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome (ACTIVE_NOT_RECRUITING) PHASE2 CT.gov search · Cochrane · PubMed	DGIdb	—
ATRACURIUM BESYLATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
ATROPINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
AVELUMAB Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
AXITINIB Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
AZACITIDINE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	DGIdb	—
AZARIBINE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BECLOMETHASONE DIPROPIONATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
BENAZEPRIL HYDROCHLORIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BENDAMUSTINE Repurposing via ATM	Small molecule	Approved	Strong	95	—	DGIdb	—
BENORILATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
BETAMETHASONE DIPROPIONATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE SODIUM PHOSPHATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BETAMETHASONE VALERATE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	ChEMBL Open Targets
BICALUTAMIDE Repurposing via AR	Small molecule	Approved	Strong	95	—	DGIdb	—
BICALUTAMIDE Repurposing via ABL1	Small molecule	Approved	Strong	95	—	ChEMBL	ChEMBL Open Targets

Natural Products

41 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked)

Reference lookups: GreenMedInfo · Examine.com

Drug	Type	Phase	Evidence	Score	Trials & literature	Sources	Links
Vitamin D3 Natural product Animal Study Vitamin D and gossypol appear to reduce lymphocyte content in Chronic L… In Vitro Study Ascorbic acid synergistically enhances the therapeutic effect of target… In Vitro Study Association of leukemia target genes Tet2, Bcl2, and Slc23a2 in vitamin…	Nutraceutical	Phase III	Emerging	10	5 trials View evidence Registry trials NCT01787409 — Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency (ACTIVE_NOT_RECRUITING) NA NCT02100423 — Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (COMPLETED) PHASE2 NCT02553447 — Cholecalciferol in Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency (COMPLETED) NA NCT03078855 — A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma (COMPLETED) PHASE3 NCT01518959 — The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases (TERMINATED) PHASE3 CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Omega-3 Fatty Acids Natural product Insect Study "Dietary polyphenols in cancer prevention: the example of the flav… In Vitro Study "Inhibition of Nuclear Factor Kappa B activation in Early-Stage Ch…	Nutraceutical	Phase II	Emerging	10	1 trials View evidence Registry trials NCT00899353 — Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM) (TERMINATED) PHASE2 CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Garlic Natural product In Vitro Study Allicin, a highly active component from freshly crushed garlic, induces…	Food compound	Preclinical	Emerging	10	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Vitamin C Natural product In Vitro Study Ascorbic acid synergistically enhances the therapeutic effect of target… Animal Study Vitamin D and gossypol appear to reduce lymphocyte content in Chronic L… In Vitro Study Association of leukemia target genes Tet2, Bcl2, and Slc23a2 in vitamin…	Nutraceutical	Preclinical	Emerging	10	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Curcumin Natural product Human Study Rice bran arabinoxylan and curcumin therapy may be of benefit to patien… In Vitro Study Curcumin (from Turmeric) increases the efficacy of chemotherapeutic age… In Vitro Study Curcumin induces apoptosis in primary resting B chronic lymphocytic leu…	Food compound	Phase II	Emerging	7	1 trials View evidence Registry trials NCT02100423 — Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (COMPLETED) PHASE2 CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Quercetin Natural product Insect Study "Dietary polyphenols in cancer prevention: the example of the flav… In Vitro Study "Inhibition of Nuclear Factor Kappa B activation in Early-Stage Ch… In Vitro Study Both fisetin and quercetin were able to augment the cytotoxic activity…	Food compound	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Berberine Natural product In Vitro Study Anti-tumor effect of berberine on chronic lymphocytic leukemia cells. In Vitro Study Apoptotic effect of berberine via Bcl-2, ROR1, and mir-21 in patients w… In Vitro Study Berberine affects mitochondrial activity and cell growth of leukemic ce…	Botanical	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Resveratrol Natural product Animal Study, In Vitro Study Wogonin treatment prevented leukemia development when given early after… In Vitro Study Resveratrol induces apoptosis in malignant lymphocytes of chronic lymph… In Vitro Study Resveratrol induces programmed cell death in human B-cell chronic lymph…	Food compound	Preclinical	Emerging	7	2 pubs View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Egcg Natural product In Vitro Study Curcumin induces programmed cell death in chronic lymphocytic leukemia… In Vitro Study Green tea contains phytochemicals (e.g. EGCG) which exhibit significant… In Vitro Study Turmeric and green tea have significant apoptic effects in chronic lymp…	Food compound	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Valerian Natural product Human Study Verbena officinalis essential oil and its component citral has apoptoic…	Botanical	Preclinical	Emerging	7	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
EGCG (Epigallocatechin Gallate) Natural product Human: Case Report A case of complete and durable molecular remission of chronic lymphocyt… In Vitro Study Curcumin induces programmed cell death in chronic lymphocytic leukemia… In Vitro Study Green tea contains phytochemicals (e.g. EGCG) which exhibit significant…	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Deguelin Natural product Animal Study, Human In Vitro These results suggest deguelin could have potential for the treatment o… In Vitro Study Deguelin induces programmed cell death in B-cell chronic lymphocytic le…	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Honokiol Natural product Animal Study, In Vitro Study Honokiol-chlorambucil co-prodrugs selectively enhance the killing effec… In Vitro Study Honokiol is a potent inducer of apoptosis in B-CLL cells.	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
St. John's Wort Natural product In Vitro Study Hyperforin (a fat-soluble compound from St. John's wort) may impro… In Vitro Study Hyperforin, a compound found with St. Johns wort, have anticancer activ…	Botanical	Phase III	Emerging	0	1 trials View evidence Registry trials NCT00005805 — St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer (COMPLETED) PHASE3 CT.gov search · Cochrane · PubMed	GreenMedInfo	PubChem GreenMedInfo
Mistletoe Natural product Human Study Mistletoe extract is known to induce apoptosis and immunactivation in c…	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Rice Bran Natural product Human Study Rice bran arabinoxylan and curcumin therapy may be of benefit to patien…	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Oleocanthal Natural product Human Study The effect of dietary intervention with high-oleocanthal and oleacein o…	Nutraceutical	Preclinical	Emerging	0	1 trials View evidence Registry trials NCT04215367 — Dietary Intervention With High Phenolic EVOO in CLL (COMPLETED) NA CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Olive Leaf Extract Natural product Human Study The effect of dietary intervention with high-oleocanthal and oleacein o…	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Citral Natural product Human Study Verbena officinalis essential oil and its component citral has apoptoic…	Nutraceutical	Preclinical	Emerging	0	No indexed hits View evidence CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Neem Natural product Human In Vitro Neem leaf extract exhibits anti-leukemic properties in patient primary…	Nutraceutical	Phase I	Emerging	0	1 trials View evidence Registry trials NCT01251250 — Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia (WITHDRAWN) PHASE1 CT.gov search · Cochrane · PubMed	GreenMedInfo	GreenMedInfo
Beet Natural product Human: Case Report Beetroot-carrot juice can be used as an effective treatment for CLL alo…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Carrot Natural product Human: Case Report Beetroot-carrot juice can be used as an effective treatment for CLL alo…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Genistein Natural product Animal Study Genistein increases the efficacy of fludarabine in inducing cell death…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Vanillic Acid Natural product Animal Study Vanillic acid protects mortality and toxicity induced by N-ethyl-N-nitr…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Cottonseed Oil (Gossypol) Natural product Animal Study Vitamin D and gossypol appear to reduce lymphocyte content in Chronic L…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Wogonin Natural product Animal Study, In Vitro Study Wogonin treatment prevented leukemia development when given early after…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Bilberry Natural product In Vitro Study An anthocyanin-rich dietary bilberry extract induced a redox-sensitive…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Fisetin Natural product In Vitro Study Both fisetin and quercetin were able to augment the cytotoxic activity…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Luteolin Natural product In Vitro Study Both fisetin and quercetin were able to augment the cytotoxic activity…	Food compound	Preclinical	Emerging	0	—	GreenMedInfo	PubChem GreenMedInfo
Chaga Mushroom (Inonotus Obliquus) Natural product In Vitro Study Compounds from chaga mushroom exhibited strong cytotoxicity against A54…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Polyphenols Natural product In Vitro Study Curcumin induces programmed cell death in chronic lymphocytic leukemia… Insect Study "Dietary polyphenols in cancer prevention: the example of the flav…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Gamma-Linoleic Acid (GLA) Natural product In Vitro Study Gamma-linolenic acid induces apoptosis in B-chronic lymphocytic leukaem…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Hyperforin Natural product In Vitro Study Hyperforin induces apoptosis of chronic lymphocytic leukemia cells. In Vitro Study Hyperforin (a fat-soluble compound from St. John's wort) may impro… In Vitro Study Hyperforin, a compound found with St. Johns wort, have anticancer activ…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Indole-3-Carbinol Natural product In Vitro Study Indole-3-carbinol synergizes with and restores fludarabine sensitivity…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Mango Natural product In Vitro Study Mangifera Indica can act promising source for anti-cancer treatment can…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Carbon 60 Natural product In Vitro Study Photocytotoxic effect of C60 fullerene against L1210 leukemic cells is…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Plumbagin Natural product In Vitro Study Plumbagin reduces chronic lymphocytic leukemia cell survival by downreg…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Tripterygium Wilfordii Natural product In Vitro Study Triptolide inhibits transcription factor NF-kappa B, which translates i…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Triptolide Natural product In Vitro Study Triptolide inhibits transcription factor NF-kappa B, which translates i…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Catechin Natural product Human: Case Report A case of complete and durable molecular remission of chronic lymphocyt… In Vitro Study Turmeric and green tea have significant apoptic effects in chronic lymp…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo
Hops Natural product In Vitro Study Xanthohumol, a compound found within hops, induces programmed cell deat…	Nutraceutical	Preclinical	Emerging	0	—	GreenMedInfo	GreenMedInfo

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.

Chronic Lymphocytic Leukaemia (CLL)

Disease overview

Remission & chronicity

Alterations

Therapeutics

Natural Products

Part of the Open Source Medicine Foundation Network